AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
Arvinas price target lowered to $81 from $87 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...
What is HC Wainwright’s Estimate for VKTX Q1 Earnings?
Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Viking Therapeutics in a research note issued on Thursday, February 6th. HC Wainwright analyst J. Pantginis expects that ...
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...
Hosted on MSN2d
HC Wainwright & Co. Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, HC Wainwright & Co. downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX ...
Largo Resources stock target cut to $3.70 at H.C. Wainwright
H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...